|Bid||133.030 x 200|
|Ask||133.040 x 500|
|Day's Range||132.340 - 134.290|
|52 Week Range||109.320 - 137.080|
|PE Ratio (TTM)||22.52|
|Dividend & Yield||3.36 (2.50%)|
|1y Target Est||N/A|
Pfizer said in the suit that J&J is offering discounts on its Remicade treatment in exchange for essentially excluding Pfizer's drug from insurance coverage, keeping it out of the hands of patients. J&J said in an e-mailed statement that the lawsuit was without merit and that the company is competing on value and price.
Back in April, Barron’s recommended buying shares of Johnson & Johnson (JNJ), arguing that the shares sold off too sharply after its first-quarter earnings report. Since then, J&J’s stock has gained 9%. Today, Goldman Sachs’s Jami Rubin told investors to find the exit.
The closely guarded world of drug pricing is getting a public airing in a feud between two of the industry’s biggest companies. The attention drawn to rebates could hurt the profits of some very successful ...